Bennett D H
Chest. 1978 Dec;74(6):624-8. doi: 10.1378/chest.74.6.624.
The effect of administration of disopyramide on the ventricular response to atrial fibrillation was studied in six patients with the Wolff-Parkinson-White syndrome. The drug was given intravenously to five patients during intracardiac electrophysiologic studies and to a sixth patient during electrocardiographic monitoring in a coronary care unit. One patient with a very rapid ventricular response to atrial fibrillation underwent a second electrophysiologic study after oral treatment for four weeks with disopyramide. In all cases, administration of disopyramide reduced the mean ventricular rate and increased the shortest interval between consecutive preexcited ventricular complexes during atrial fibrillation. Therapy with disopyramide should therefore be useful in preventing ventricular fibrillation which can result from a rapid ventricular response to atrial fibrillation in patients with an accessory atrioventricular pathway. There has been no recurrence of paroxysmal tachycardia in the four patients who have been maintained on oral therapy with disopyramide.
在6例预激综合征患者中研究了丙吡胺给药对心房颤动时心室反应的影响。在心脏内电生理研究期间，对5例患者静脉给予该药物，在冠心病监护病房对第6例患者进行心电图监测时给予该药物。1例对心房颤动心室反应极快的患者在口服丙吡胺治疗4周后接受了第二次电生理研究。在所有病例中，丙吡胺给药均降低了平均心室率，并增加了心房颤动期间连续预激心室复合波之间的最短间期。因此，丙吡胺治疗对于预防因房室旁路导致的心房颤动快速心室反应所引起的心室颤动应是有用的。在接受丙吡胺口服治疗的4例患者中，阵发性心动过速未再复发。
